Tirzepatide emerges a groundbreaking treatment agent for individuals struggling type 2 diabetes. As a dual receptor activator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent check here insulinotropic polypeptide (GIP) receptors, leading synergistic effects on blood glucose control. By increasing insulin secretion while si